Avanos Medical

Avanos Medical, Inc. is a United States medical technology company focused on clinical devices used in acute care, chronic care, pain management, and digestive health. Its portfolio is organized around two principal franchises, Pain Management and Chronic Care. The company positions these businesses around improving clinical outcomes, supporting faster recovery, reducing avoidable complications, and helping healthcare providers limit reliance on opioids where non-opioid treatment options are appropriate. The company’s products are used across hospitals, clinics, and other healthcare settings. Its portfolio includes devices for gastrointestinal decompression and enteral access, respiratory care, infection prevention, and interventional pain treatment. One of its best-known systems is the Cortrak 2 Enteral Access System, which is designed to assist qualified healthcare professionals in placing feeding tubes by providing real-time guidance during the procedure. The system is intended to support safer and more efficient placement, while helping nurses, dietitians, gastroenterology specialists, and intensive-care clinicians manage patients who require enteral nutrition. Avanos also markets products associated with pain-management procedures and recovery. These include technologies used in regional anesthesia and other interventional approaches intended to provide alternatives or complements to systemic opioid medication. Its chronic-care activities cover products used in long-term patient management, nutrition delivery, respiratory care, and infection-control workflows. The company’s business therefore spans both procedural equipment and disposable or recurring-use clinical products. Avanos emerged from the healthcare-products operations formerly associated with Halyard Health. The Avanos name was introduced as part of the company’s effort to establish a more focused medical-technology identity after the separation of Halyard’s medical-device business from Kimberly-Clark. The company subsequently operated as a stand-alone publicly traded medical-device business under the ticker AVNS. The company sells products in more than 90 countries and maintains a network of medical-device manufacturing facilities. Its customers include hospitals, healthcare systems, clinicians, and distributors. Avanos competes in specialized segments rather than presenting itself as a broad-based hospital conglomerate: its emphasis is on focused clinical technologies that address pain, nutrition access, respiratory care, infection prevention, and related acute- and chronic-care needs. Regulatory compliance and product safety are important aspects of Avanos’s operations. In April 2022, the company issued a voluntary field correction involving the Cortrak 2 system after concerns that use of the device in certain circumstances could contribute to serious patient injury or death. The event drew attention to the importance of following the system’s instructions, training requirements, and verification procedures. Avanos continued to describe the system as a clinical aid rather than a substitute for professional judgment and required corrective actions for affected users. Avanos remains a public medical-technology company with an internationally distributed product portfolio. Its core strategic themes are chronic-care management, procedural pain relief, enteral access, respiratory and infection-related care, and the development of devices that can improve clinical workflow while reducing risks associated with invasive treatment or opioid use.

Avanos Medical developed from a medical-device business that had previously been operated within Halyard Health. Halyard Health itself was created through the separation of Kimberly-Clark’s healthcare business, allowing the medical-products operations to function as an independent public company. Avanos was subsequently adopted as the corporate identity as the business sought to distinguish itself as a focused medical-technology company rather than as a diversified healthcare-products manufacturer. The company’s strategic scope centers on two broad franchises: Pain Management and Chronic Care. Pain Management includes products used in interventional procedures and regional anesthesia, with the broader objective of providing clinicians with non-opioid or opioid-sparing options. This positioning reflects the medical sector’s concern about opioid exposure and the need for treatment approaches that can manage pain while supporting mobility and recovery. The Chronic Care franchise covers products for patients requiring ongoing clinical support. These activities include enteral access, gastrointestinal decompression, respiratory care, infection prevention, and related hospital or long-term-care workflows. A significant part of this portfolio is the Cortrak 2 Enteral Access System, also referred to in company materials as part of the Cortrak family. The system is designed to help trained healthcare professionals place feeding tubes with the assistance of real-time anatomical guidance. Its intended users include nurses, dietitians, gastroenterology clinicians, and intensive-care physicians. Avanos’s products are sold through a combination of direct commercial activity and distribution arrangements. The company has reported an international presence spanning more than 90 countries and operates principal manufacturing facilities supporting its medical-device portfolio. Rather than competing as a general hospital operator or a comprehensive hospital-systems supplier, Avanos concentrates on selected clinical categories where specialized devices and consumables can influence procedure efficiency, patient safety, infection control, and recovery. In April 2022, Avanos reported a voluntary field correction involving the Cortrak 2 system. The issue was significant because incorrect or insufficiently verified feeding-tube placement can expose patients to serious harm, including the possibility of injury or death. The corrective action highlighted the need for appropriate operator training, adherence to instructions for use, and confirmation of tube placement through established clinical procedures. The event became an important part of the company’s regulatory and product-safety history, although the available reference material does not establish that it was a finding of intentional misconduct. Avanos continued to operate as a publicly traded medical-technology company under the AVNS ticker during the period covered by the available reference material. Its business remained focused on acute and chronic care, pain management, and products supporting clinicians in hospital and procedural settings. The company’s commercial narrative combined clinical specialization with recurring-use medical products and technologies designed to reduce workflow burden. Reference material also reports a later ownership transaction. In April 2026, Avanos agreed to be acquired by affiliates of American Industrial Partners, and the transaction was reported as completed in July 2026. If confirmed by definitive transaction and company filings, this would mark a major transition in Avanos’s corporate history by moving the business from public-market ownership to ownership by an investment firm’s affiliates. The available material does not provide transaction consideration, detailed conditions, or post-closing organizational information.

1. 2026Agreement to be acquired by American Industrial Partners affiliates

   Reference material reports that Avanos agreed to an acquisition by affiliates of American Industrial Partners in April 2026.

   Source
2. 2026Reported completion of acquisition

   Reference material reports that the acquisition by American Industrial Partners affiliates was completed in July 2026.

   Source
3. 2022Voluntary Cortrak 2 field correction

   Avanos issued a voluntary field correction for the Cortrak 2 enteral access system after concerns that use in certain circumstances could lead to serious patient injury or death.

   Source
4. 2018Avanos identity adopted

   The medical-device business associated with Halyard Health adopted the Avanos Medical identity as part of its development as an independent, focused medical-technology company.

   Source
5. 2014Avanos Medical business established

   Avanos Medical is identified as having been founded in 2014 and developed as a focused medical-technology business serving acute-care, chronic-care, and pain-management markets.

   Source

A focused medical-technology company providing clinical devices intended to improve patient recovery, support safer care delivery, reduce complications, and expand non-opioid approaches to pain management.

• Cortrak 2 Enteral Access SystemEnteral access

  The Cortrak 2 is a clinical guidance system intended to assist trained healthcare professionals with the placement of feeding tubes. It provides real-time guidance during the procedure and is marketed as a workflow-support tool for nurses, dietitians, gastroenterology clinicians, and intensive-care teams. The device is designed to support safer and more efficient enteral access, but its use requires appropriate training, adherence to instructions, and clinical verification.

• Gastrointestinal decompression systemsAcute care

  Avanos markets devices used for gastrointestinal decompression in hospital care. These products support the management of patients who require removal of gastric or intestinal contents and are intended to integrate into acute-care workflows. They form part of the company’s chronic-care and enteral-access portfolio, alongside products used for nutrition delivery and tube management.

• Pain-management technologiesPain management

  Avanos’s Pain Management franchise includes devices used in interventional pain procedures and regional anesthesia. The portfolio is positioned to help clinicians manage pain through targeted treatment and to support opioid-sparing approaches where clinically suitable. Specific products and indications vary by market and regulatory authorization.

• Respiratory-care productsRespiratory care

  Respiratory-care products form part of Avanos’s broader chronic-care and hospital-care offering. They are intended to support respiratory treatment and related clinical workflows. The available reference material does not provide a complete product-level listing or individual launch dates.

• Infection-prevention productsInfection prevention

  Avanos includes infection prevention among the clinical objectives addressed by its product portfolio. These products support healthcare providers in reducing infection-related risks associated with patient care and medical procedures. The supplied reference material does not identify individual product names or launch dates.

• 2026Acquisition by American Industrial Partners affiliatesM&A

  Reference material reports that Avanos agreed to be acquired by affiliates of American Industrial Partners in April 2026.

  What changed. The reported transaction would transfer Avanos from public-company ownership to ownership by affiliates of American Industrial Partners.

  Aftermath. The acquisition was reported as completed in July 2026. The available material does not provide the purchase price, detailed transaction terms, or the company’s post-closing operating structure.

  Source
• 2022Voluntary field correction for Cortrak 2Other

  A field correction was initiated after concerns that use of the Cortrak 2 enteral access system in certain circumstances could contribute to serious injury or death.

  What changed. Avanos issued a voluntary correction and communicated corrective-use requirements concerning the system, including the importance of appropriate training, adherence to instructions, and clinical verification.

  Aftermath. The action increased scrutiny of the system’s use and became a notable product-safety event in Avanos’s history. The available material does not establish a financial settlement or intentional misconduct.

  Source

• 2026Avanos agrees to acquisition by affiliates of American Industrial Partners

  Reference material reports that Avanos agreed to be acquired by affiliates of American Industrial Partners in April 2026, with completion reported in July 2026. The transaction would change the company’s ownership structure from a publicly traded medical-technology business to an affiliate-owned company.

  M&A
  Source
• 2022Avanos issues voluntary field correction for Cortrak 2 enteral access system

  Avanos issued a voluntary field correction concerning the Cortrak 2 system after identifying circumstances in which use of the device could contribute to serious injury or death. The corrective action focused on clinical use, training, and verification procedures for feeding-tube placement.

  RecallRegulation
  Source

1. Avanos Medical
2. Avanos Medical official website